Urology News and Research

Latest Urology News and Research

New imaging technique measurably improves prostate cancer screening

In 2014, prostate cancer was the leading cause of newly diagnosed cancers in men and the second leading cause of cancer death in men. Writing in the January 6, 2015 issue of the journal Prostate Cancer and Prostatic Disease, a team of scientists and physicians from the University of California, San Diego School of Medicine, with counterparts at University of California, Los Angeles, describe a novel imaging technique that measurably improves upon current prostate imaging - and may have significant implications for how patients with prostate cancer are ultimately treated.

6 Jan 2015

FDA receives Actavis' NDA resubmission for cariprazine

Actavis plc (NYSE: ACT) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of Actavis' New Drug Application (NDA) resubmission for its atypical antipsychotic cariprazine, a potent dopamine D3/D2 receptor partial agonist with preferential binding to D3 receptors.

6 Jan 2015

Negative health effects of severe obesity

The negative health effects of severe obesity are very well known and have been thoroughly documented, yet obesity levels in the United States continue to remain stubbornly high. Many of these repercussions are life threatening and include heart attack, stroke, and a greatly increased chance of developing cancer.

27 Dec 2014

Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension

Actavis plc today confirmed that the Company has received a complete response letter from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for the fixed-dose combination (FDC) of nebivolol and valsartan for the treatment of hypertension.

25 Dec 2014

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Actavis plc and Adamas Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Namzaric, a fixed-dose combination (FDC) of memantine hydrochloride extended-release, a NMDA receptor antagonist, and donepezil hydrochloride, an acetylcholinesterase inhibitor.

25 Dec 2014

Laparoscopic radical cystectomy can lead to reliable, long-term cancer control

Long-term survival rates following laparoscopic surgery for bladder cancer are comparable to those of open surgery, according to a study published in BJU International. The findings, which come from the largest study to date with long-term follow-up after this type of minimally invasive surgery, indicate that prospective randomized trials comparing these two bladder cancer surgeries are warranted.

18 Dec 2014

R. Geigy Foundation recognizes scientific endeavours in neglected disease research, public health

The R. Geigy Foundation honours two scientific endeavours in neglected disease research and public health. It confers the R. Geigy Award (10'000 CHF) to the Laotian scientists Somphou Sayasone and the Jubilee Award (70'000) to the project "Connecting the Dots" proposed by the Swiss Tropical and Public Health Institute.

18 Dec 2014

Top ten priorities for research into management of Parkinson's

Patients with Parkinson's, medics and carers have identified the top ten priorities for research into the management of the condition in a study by the University of East Anglia and Parkinson's UK.

16 Dec 2014

Olympus receives FDA clearance for Narrow Band Imaging

Olympus, a global technology leader in designing and delivering innovative solutions for medical and surgical procedures, among other core businesses, announced today FDA 510(k) clearance of Narrow Band Imaging (NBI) as enabling effective targeting of biopsies not seen under white light and improved visualization of tumor boundaries in Non-Muscle-Invasive Bladder Cancer (NMIBC) patients.

From Evident Corporation - Life Sciences 15 Dec 2014

Study: Patients with operable kidney cancers more likely to have partial nephrectomy

Patients with operable kidney cancers were more likely to have a partial nephrectomy -- the recommended treatment for localized tumors -- when treated in hospitals that were early adopters of robotic surgery, according to a new study.

14 Dec 2014

Two MinuteClinic walk-in medical clinics open inside CVS/pharmacy stores in Northern Nevada

Two MinuteClinic walk-in medical clinics opened today inside CVS/pharmacy stores in Reno and Sparks. They join eight MinuteClinic locations inside select CVS/pharmacy stores in the Las Vegas area in Southern Nevada.

14 Dec 2014

Researchers identify way to assess women at increased risk for UTI after pelvic-floor surgery

Researchers at Loyola University Chicago Stritch School of Medicine may have identified a way to assess who is at risk for developing a urinary tract infection (UTI) following pelvic-floor surgery.

11 Dec 2014

Highly-paid doctors make more money by ordering multiple procedures for patients: UCLA

In results characterized as "very surprising," UCLA researchers found for the first time that higher-earning clinicians make more money by ordering more procedures and services per patient rather than by seeing more patients, which may not be in patients' best interest.

9 Dec 2014

Simple rectal swab cultures can thwart drug-resistant E. coli in patients undergoing TRUSBx procedures

Some infections after prostate biopsy due to drug-resistant Escherichia coli can be thwarted by simple rectal swab cultures prior to the procedure. The cultures test for antibiotic-resistant E. coli, and the findings are used to direct the selection of antimicrobial prophylaxis used for the procedure, according to Rhode Island Hospital researchers.

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

Weight-loss surgery may reduce lower urinary tract symptoms

Metabolic syndrome is linked with an increased frequency and severity of lower urinary tract symptoms, but weight loss surgery may lessen these symptoms. The findings, which come from two studies published in BJU International, indicate that urinary problems may be added to the list of issues that can improve with efforts that address altered metabolism.

8 Dec 2014

Nivolumab drug highly effective for Hodgkin's lymphoma

A phase I clinical trial of nivolumab found that the immune-boosting drug is a highly effective therapy for Hodgkin's lymphoma. The multi-institution study, led by Mayo Clinic, indicated that the drug was safe and led to an 87 percent response rate in patients who had failed on other treatments.

7 Dec 2014

Study links poor semen quality to higher risk of various health conditions

A study of more than 9,000 men with fertility problems has revealed a correlation between the number of different defects in a man's semen and the likelihood that the man has other health problems.

6 Dec 2014

Malnutrition predicts long-term survival in elderly patients undergoing Whipple procedure

Malnutrition is an important factor predicting long-term survival in older patients undergoing pancreaticoduodenectomy (PD) (commonly called the Whipple procedure) to treat benign tumors and cysts of the pancreas as well as pancreatitis, according to new study results published in the December issue of the Journal of the American College of Surgeons.

6 Dec 2014

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Actavis plc today announced that the Anti-Infective Drugs Advisory Committee convened by the U.S. Food and Drug Administration has voted to recommend approval of Actavis' New Drug Application (NDA) for ceftazidime-avibactam, an investigational antibiotic being developed to treat hospitalized patients when limited or no treatment options are available for complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) (including acute pyelonephritis) caused by Gram-negative pathogens.

5 Dec 2014

Urology News and Research

Latest Urology News and Research

New imaging technique measurably improves prostate cancer screening

FDA receives Actavis' NDA resubmission for cariprazine

Negative health effects of severe obesity

Actavis receives complete response letter for nebivolol/valsartan FDC for treatment of hypertension

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Laparoscopic radical cystectomy can lead to reliable, long-term cancer control

R. Geigy Foundation recognizes scientific endeavours in neglected disease research, public health

Top ten priorities for research into management of Parkinson's

Olympus receives FDA clearance for Narrow Band Imaging

Study: Patients with operable kidney cancers more likely to have partial nephrectomy

Two MinuteClinic walk-in medical clinics open inside CVS/pharmacy stores in Northern Nevada

Researchers identify way to assess women at increased risk for UTI after pelvic-floor surgery

Highly-paid doctors make more money by ordering multiple procedures for patients: UCLA

Simple rectal swab cultures can thwart drug-resistant E. coli in patients undergoing TRUSBx procedures

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Weight-loss surgery may reduce lower urinary tract symptoms

Nivolumab drug highly effective for Hodgkin's lymphoma

Study links poor semen quality to higher risk of various health conditions

Malnutrition predicts long-term survival in elderly patients undergoing Whipple procedure

FDA Advisory Committee votes in favor of Actavis' ceftazidime-avibactam

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Urology News and Research

Latest Urology News and Research

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Newsletters you may be interested in